Interní Med. 2010; 12(1): 8-17

Is hypertension treatment affected by the presence of comorbidities?

prof.MUDr.Jan Bultas, CSc.
Ústav farmakologie 3. LF UK, Praha

Hypertension treatment is not invariably a simple task with the optimal treatment strategy being affected by a number of factors: age,

associated conditions, blood pressure level, concurrent medications, patient compliance and numerous other variables. Selecting the

most appropriate medication, which on the one hand will best contribute to improving the patient‘s prognosis and on the other hand

will be well tolerated, depends on determining and respecting these features. The present review is concerned with the current opinions

on the treatment of hypertension in diabetics, in patients with kidney disease, heart failure and heart valve defects, or in the elderly.

Keywords: arterial hypertension, treatment, diabetes, ischaemic heart disease, stroke, nephropathy, heart valve defects

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bultas J. Is hypertension treatment affected by the presence of comorbidities? Interní Med. 2010;12(1):8-17.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Verdecchia P, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009, 15;374 (9689): 525-533 What is what? 7 ed. Exerpta Medica, Sweden 2006. Go to original source...
    2. Stump CS, et al. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006; 81 (6): 796-806. Go to original source... Go to PubMed...
    3. MacKinnon M, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2007, 49(3): 497. Go to original source... Go to PubMed...
    4. Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004; 30(6): 487-496. Go to original source... Go to PubMed...
    5. Elliott WJ, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007 20; 369(9557): 201-207. Go to original source... Go to PubMed...
    6. Bultas J, et al. Effect of metipranolol (trimepranolol) on lipoprotein fractions in short-term and long-term administration. Cas Lek Cesk. 1983; 122(35): 1067-1069. Go to PubMed...
    7. Iaccarino G, et al. Beta-blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene. Pharmacogenomics J. 2005; 5(5): 292-297. Go to original source... Go to PubMed...
    8. Sue-Anne Toh, et al. Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers. Expert Review of Cardiovascular Therapy, 2008, 6(7): 1007-1022. Go to original source... Go to PubMed...
    9. Cosin J, et al. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002 A; 4(4): 507-513. Go to original source... Go to PubMed...
    10. Laragh JH, et al. K+ Depletion and the Progression of Hypertensive Disease or Heart Failure. The Pathogenic Role of Diuretic-Induced Aldosterone Secretion. Hypertension 2001; 37: 806-809. Go to original source... Go to PubMed...
    11. Khan M, et al. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174 (12): 1737-1742. Go to original source... Go to PubMed...
    12. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004 (15): 1341-1362.
    13. Ho PM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008; 155(4): 772-779. Go to original source... Go to PubMed...
    14. Klein W. Antihypertensive therapy and modification of metabolic risk factors (glucose and lipid metabolism). Z Kardiol. 1992; 81 (6): 295-302.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.